financetom
Business
financetom
/
Business
/
Cloudflare Q1 Non-GAAP Earnings, Revenue Increase; Sets Guidance -- Shares Fall After-Hours
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cloudflare Q1 Non-GAAP Earnings, Revenue Increase; Sets Guidance -- Shares Fall After-Hours
May 2, 2024 2:13 PM

04:59 PM EDT, 05/02/2024 (MT Newswires) -- Cloudflare ( NET ) reported Q1 non-GAAP earnings Thursday of $0.16 per diluted share, up from $0.08 a year earlier.

Analysts surveyed by Capital IQ expected $0.13.

Revenue for the quarter ended March 31 was $378.6 million, up from $290.2 million a year earlier.

Analysts surveyed by Capital IQ expected $373.4 million.

The company said it expects Q2 non-GAAP earnings of $0.14 per share. Analysts surveyed by Capital IQ expected $0.13. The company expects revenue for the quarter of $393.5 million to $394.5 million. Analysts expected $393.5 million.

Cloudflare ( NET ) raised full-year 2024 non-GAAP earnings estimates to the range of $0.60 to $0.61 per share from previous guidance of $0.58 to $0.59 per share. Analysts surveyed by Capital IQ expected $0.58. The company reiterated its revenue outlook of $1.648 billion to $1.652 billion. Analysts expected $1.65 billion.

Shares of the company fell about 14% in after-hours activity.

Price: 76.25, Change: -12.72, Percent Change: -14.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
Aug 2, 2024
Thursday, the FDA approved Adaptimmune Therapeutics ( ADAP ) plc’s Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma, a rare type of cancer that tends to occur near large joints, mainly the knees. The approval covers patients who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen. This indication is approved under...
Sector Update: Consumer
Sector Update: Consumer
Aug 2, 2024
08:48 AM EDT, 08/02/2024 (MT Newswires) -- Consumer stocks were mixed premarket Friday as the Consumer Staples Select Sector SPDR Fund (XLP) was up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) fell by 3.6% recently. Church & Dwight ( CHD ) shares fell by more than 4% after the consumer goods company said it expects Q3 adjusted...
Atmus Filtration Q2 Adjusted Earnings, Sales Rise; 2024 Outlook Updated -- Shares Gain Pre-Bell
Atmus Filtration Q2 Adjusted Earnings, Sales Rise; 2024 Outlook Updated -- Shares Gain Pre-Bell
Aug 2, 2024
08:51 AM EDT, 08/02/2024 (MT Newswires) -- Atmus Filtration Technologies ( ATMU ) reported Q2 adjusted earnings Friday of $0.71 per diluted share, up from $0.63 a year earlier. Analysts polled by Capital IQ expected $0.58. Net sales for the quarter ended June 30 were $432.6 million, up from $413.6 million a year earlier. Analysts surveyed by Capital IQ expected...
Plains GP Holdings Q2 Net Income Falls, Revenue Rises
Plains GP Holdings Q2 Net Income Falls, Revenue Rises
Aug 2, 2024
08:51 AM EDT, 08/02/2024 (MT Newswires) -- Plains GP Holdings ( PAGP ) reported Q2 net income Friday of $0.20 per diluted share, down from $0.25 a year earlier. Four analysts polled by Capital IQ expected $0.20. Revenue for the quarter ended June 30 was $12.93 billion, up from $11.6 billion a year earlier. Three analysts surveyed by Capital IQ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved